- SEK2.01bn
- SEK1.43bn
Brief: Index Pharmaceuticals Says Co Has Entered Into A Conditional Agreement Regarding A Reverse Merger With Flerie
Brief: Index Pharmaceuticals Says No Dividend Shall Be Paid For Financial Year 2023.
Brief: InDex Pharmaceuticals Q1 EBIT SEK -5.3 Million
Brief: InDex Pharmaceuticals To Proceed With Reverse Merger
Brief: CEO And CFO Both To Leave Index Pharmaceuticals
Brief: Index Pharmaceuticals Says Co Will Not Proceed With Development Of Any Of Its Other Compounds
Brief: Index Pharmaceuticals Evaluates Strategic Alternatives
Brief: InDex Pharmaceuticals Q4 EBIT SEK -107.9 Million
Brief: Index Pharmaceuticals Expected Cash Balance Per March 31 SEK 180-190 Mln
Brief: InDex Pharmaceuticals Q3 EBIT SEK -42.1 Million
Brief: Index Pharmaceuticals Discontinues cobitolimod Phase III Program
Brief: Index Pharmaceuticals Gets New Patent For Cobitolimod In South Korea
Brief: Index Pharmaceuticals Granted New Patent For cobitolimod In South Korea
Brief: Index Pharmaceuticals Holding Expects To Have Recruited 30% Of Patients In Induction Study 1 in Q3
Brief: InDex Pharmaceuticals Q2 EBIT at SEK -86.9 Million
Brief: Index Pharmaceuticals Gets Cobitolimod Patent in Europe
Brief: Index Pharmaceuticals Announces License Agreement With Viatris Japan To Develop And Commercialize Cobitolimod In Japan
Brief: InDex Pharmaceuticals Q1 EBIT Loss at SEK 44.3 Million
Brief: InDex Pharmaceuticals Announces Positive Results From PK Study With Cobitolimod